GB201900528D0 - Bicyclic peptide ligands specific for integrin AVB3 - Google Patents

Bicyclic peptide ligands specific for integrin AVB3

Info

Publication number
GB201900528D0
GB201900528D0 GBGB1900528.9A GB201900528A GB201900528D0 GB 201900528 D0 GB201900528 D0 GB 201900528D0 GB 201900528 A GB201900528 A GB 201900528A GB 201900528 D0 GB201900528 D0 GB 201900528D0
Authority
GB
United Kingdom
Prior art keywords
peptide ligands
ligands specific
bicyclic peptide
integrin avb3
avb3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1900528.9A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BicycleRD Ltd
Original Assignee
BicycleRD Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BicycleRD Ltd filed Critical BicycleRD Ltd
Priority to GBGB1900528.9A priority Critical patent/GB201900528D0/en
Publication of GB201900528D0 publication Critical patent/GB201900528D0/en
Priority to EP20701836.7A priority patent/EP3965892A1/en
Priority to PCT/GB2020/050072 priority patent/WO2020148528A1/en
Priority to CN202080020233.1A priority patent/CN113613728A/zh
Priority to JP2021563434A priority patent/JP2022517698A/ja
Priority to US17/422,938 priority patent/US20220119488A1/en
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546Integrin superfamily
    • C07K14/70557Integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB1900528.9A 2019-01-15 2019-01-15 Bicyclic peptide ligands specific for integrin AVB3 Ceased GB201900528D0 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
GBGB1900528.9A GB201900528D0 (en) 2019-01-15 2019-01-15 Bicyclic peptide ligands specific for integrin AVB3
EP20701836.7A EP3965892A1 (en) 2019-01-15 2020-01-15 Bicyclic peptide ligands specific for integrin alpha v beta 3
PCT/GB2020/050072 WO2020148528A1 (en) 2019-01-15 2020-01-15 BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR INTEGRIN αVβ3
CN202080020233.1A CN113613728A (zh) 2019-01-15 2020-01-15 整联蛋白αvβ3特异性的双环肽配体
JP2021563434A JP2022517698A (ja) 2019-01-15 2020-01-15 インテグリンαvβ3に特異的な二環式ペプチドリガンド
US17/422,938 US20220119488A1 (en) 2019-01-15 2020-01-15 Bicyclic peptide ligands specific for integrin alpha-v-beta-3

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1900528.9A GB201900528D0 (en) 2019-01-15 2019-01-15 Bicyclic peptide ligands specific for integrin AVB3

Publications (1)

Publication Number Publication Date
GB201900528D0 true GB201900528D0 (en) 2019-03-06

Family

ID=65528176

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1900528.9A Ceased GB201900528D0 (en) 2019-01-15 2019-01-15 Bicyclic peptide ligands specific for integrin AVB3

Country Status (6)

Country Link
US (1) US20220119488A1 (enExample)
EP (1) EP3965892A1 (enExample)
JP (1) JP2022517698A (enExample)
CN (1) CN113613728A (enExample)
GB (1) GB201900528D0 (enExample)
WO (1) WO2020148528A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107148425B (zh) 2014-10-29 2021-08-03 拜斯科阿迪有限公司 对mt1-mmp特异性的双环肽配体
EP3645549A1 (en) 2017-06-26 2020-05-06 BicycleRD Limited Bicyclic peptide ligands with detectable moieties and uses thereof
JP7670481B2 (ja) 2017-08-04 2025-04-30 バイスクルテクス・リミテッド Cd137に対して特異的な二環式ペプチドリガンド
CN111902429A (zh) 2018-02-23 2020-11-06 拜斯科技术开发有限公司 多聚体双环肽配体
IL279489B2 (en) 2018-06-22 2025-10-01 Bicycletx Ltd Bicyclic peptide ligands specific for nectin-4, a drug conjugate containing the peptide ligands and a pharmaceutical composition containing the drug conjugate
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
US12492224B2 (en) 2018-12-21 2025-12-09 Bicycletx Limited Bicyclic peptide ligands specific for PD-L1
WO2020128527A1 (en) 2018-12-21 2020-06-25 Bicyclerd Limited Bicyclic peptide ligands specific for pd-l1
GB201900529D0 (en) 2019-01-15 2019-03-06 Bicycletx Ltd Bicyclic peptide ligands specific for CD38
TWI860386B (zh) 2019-07-30 2024-11-01 英商拜西可泰克斯有限公司 異質雙環肽複合物
AU2021322934A1 (en) 2020-08-03 2023-03-30 Bicycletx Limited Peptide-based linkers
BR102021016135A2 (pt) * 2021-08-16 2023-02-23 Novageia Biotecnologia Ltda Antagonistas miméticos macrocíclicos com atividade biológica, seus usos e composições
CN114656525B (zh) * 2022-04-25 2024-02-02 合肥师范学院 用于癌细胞整合素的rgd环肽及其在制备肿瘤药物中的应用
WO2026002154A1 (en) * 2024-06-27 2026-01-02 Syneron Opal Cell penetrating peptide compounds and using thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1452868A2 (en) 2003-02-27 2004-09-01 Pepscan Systems B.V. Method for selecting a candidate drug compound
WO2006078161A1 (en) 2005-01-24 2006-07-27 Pepscan Systems B.V. Binding compounds, immunogenic compounds and peptidomimetics
EP2653545A1 (en) 2008-02-05 2013-10-23 Bicycle Therapeutics Limited Methods and compositions
US9073974B2 (en) * 2009-12-21 2015-07-07 The Regents Of The University Of California RGD-containing cyclic peptides
CN107148425B (zh) * 2014-10-29 2021-08-03 拜斯科阿迪有限公司 对mt1-mmp特异性的双环肽配体
EP3645549A1 (en) * 2017-06-26 2020-05-06 BicycleRD Limited Bicyclic peptide ligands with detectable moieties and uses thereof
GB201810329D0 (en) * 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to integrin avB3
GB201900527D0 (en) * 2019-01-15 2019-03-06 Bicycletx Ltd Bicyclic peptide ligands specific for integrin avb3

Also Published As

Publication number Publication date
JP2022517698A (ja) 2022-03-09
WO2020148528A1 (en) 2020-07-23
EP3965892A1 (en) 2022-03-16
CN113613728A (zh) 2021-11-05
US20220119488A1 (en) 2022-04-21

Similar Documents

Publication Publication Date Title
GB201900528D0 (en) Bicyclic peptide ligands specific for integrin AVB3
GB201900527D0 (en) Bicyclic peptide ligands specific for integrin avb3
ZA202100442B (en) Bicyclic peptide ligands specific for nectin-4
IL287881A (en) Ox40-specific bicyclic peptide ligands
IL283873B1 (en) Bicyclic peptide ligands specific for MT1-MMP
SG11202106082TA (en) Bicyclic peptide ligands specific for mt1-mmp
GB201810329D0 (en) Peptide ligands for binding to integrin avB3
GB201820295D0 (en) Bicyclic peptide ligands specific for MT1-MMP
GB201820320D0 (en) Bicyclic peptide ligands specific for FAPalpha
GB201701770D0 (en) Bicyclic peptide ligands specific for integrin AVB3
GB201800598D0 (en) Bicycle peptide ligands specific for integrin AVB3
GB201918495D0 (en) Bicyclic peptide ligands specific for il-46
GB201904632D0 (en) Bicyclic peptide ligands specific for nectin-4
GB201905631D0 (en) Bicyclic peptide ligands specific for pd-l1
GB201904622D0 (en) Bicyclic peptide ligands specific for pd-l1
GB201904621D0 (en) Bicyclic peptide ligands specific for PD-L1
GB201918489D0 (en) Bicyclic peptide ligands specific for hsp90
GB201918496D0 (en) Bicyclic peptide ligands specific for klk5
GB201918497D0 (en) Bicyclic peptide ligands specific for klk7
GB201820956D0 (en) Bicyclic peptide ligands specific for pd-l1
GB201818499D0 (en) Bicyclic peptide ligands specific for nectin-4
GB201815684D0 (en) Bicyclic peptide ligands specific for nectin-4
GB201918488D0 (en) Bicyclic peptide ligands specific for chymase
HK40067671A (en) BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR INTEGRIN αVβ3
HK40067672A (en) BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR INTEGRIN αVβ3

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)